Bicara Therapeutics Inc. $BCAX Stock Holdings Raised by Vestal Point Capital LP

Key Points

• Vestal Point Capital LP increased its stake in Bicara Therapeutics by 290%, owning approximately 2.77 million shares, which represents 2.6% of its portfolio.
• Bicara Therapeutics reported a loss of ($0.50) per share, surpassing analyst estimates and is expected to post a loss of ($2.59) for the current year.
• Analysts have varying ratings on Bicara Therapeutics, with a consensus rating of "Buy" and an average price target of $32.25.

Vestal Point Capital LP boosted its position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 290.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 2,768,975 shares of the company's stock after acquiring an additional 2,058,975 shares during the period. Bicara Therapeutics comprises approximately 2.6% of Vestal Point Capital LP's holdings, making the stock its 11th biggest holding. Vestal Point Capital LP owned 5.08% of Bicara Therapeutics worth $36,080,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Red Tree Management LLC purchased a new stake in Bicara Therapeutics in the 4th quarter worth approximately $55,230,000. Braidwell LP grew its stake in Bicara Therapeutics by 8.1% in the 1st quarter. Braidwell LP now owns 2,162,803 shares of the company's stock worth $28,181,000 after acquiring an additional 162,144 shares during the period. Deep Track Capital LP boosted its holdings in shares of Bicara Therapeutics by 151.0% in the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the company's stock valued at $34,840,000 after purchasing an additional 1,203,148 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Bicara Therapeutics by 84.0% in the 1st quarter. Wellington Management Group LLP now owns 1,394,676 shares of the company's stock valued at $18,173,000 after purchasing an additional 636,708 shares during the last quarter. Finally, Blackstone Inc. boosted its holdings in shares of Bicara Therapeutics by 40.5% in the 4th quarter. Blackstone Inc. now owns 913,060 shares of the company's stock valued at $15,906,000 after purchasing an additional 263,060 shares during the last quarter.

Wall Street Analyst Weigh In

BCAX has been the topic of a number of research analyst reports. Wedbush reiterated an "outperform" rating and issued a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, August 12th. Wells Fargo & Company upgraded shares of Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price target on the stock in a report on Friday, May 23rd. Wall Street Zen lowered shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. HC Wainwright reduced their target price on shares of Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a report on Friday, August 22nd. Finally, Piper Sandler began coverage on shares of Bicara Therapeutics in a report on Monday, August 18th. They set an "overweight" rating and a $36.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $32.25.

Bicara Therapeutics Stock Performance

Bicara Therapeutics stock remained flat at $12.06 during midday trading on Friday. 359,671 shares of the company traded hands, compared to its average volume of 273,109. Bicara Therapeutics Inc. has a 12-month low of $7.80 and a 12-month high of $28.09. The stock has a market cap of $657.99 million and a price-to-earnings ratio of -3.80. The company has a 50-day simple moving average of $10.94 and a 200 day simple moving average of $11.84.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.04. On average, equities research analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.